A soluble tumor necrosis factor receptor 2 (TNFRII) mutant has an amino acid substitution at position 92Glu compared with the wild TNFRII. The mutant improves the cytotoxicity capacity of neutralizing TNFalpha and lymphotoxin. The mutant and fusion protein comprising it are useful for the treatment of TNFalpha and lymphotoxin related diseases.
一种可溶性肿瘤坏死因子受体 2(TNFRII)突变体与野生 TNFRII 相比,在 92Glu 位发生了
氨基酸置换。突变体提高了中和 TNFalpha 和淋巴毒素的细胞毒性能力。突变体及其融合蛋白可用于治疗与 TNFalpha 和淋巴毒素相关的疾病。